- Home
- QS vs NAMS Comparison
QS vs NAMS Comparison
Compare QS & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QS | NAMS |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | QS | NAMS |
|---|---|---|
| Price | $4.92 | $29.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $9.38 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 24.2M | 961.2K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.15 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | $1,827.70 | $540.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.97 | $21.14 |
| 52 Week High | $19.07 | $42.21 |
Technical Indicators
Market Signals| Indicator | QS | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 28.53 | 41.00 |
| Support Level | N/A | $29.23 |
| Resistance Level | $7.21 | $37.29 |
| Average True Range (ATR) | 0.39 | 1.88 |
| MACD | -0.12 | -0.42 |
| Stochastic Oscillator | 7.02 | 8.00 |
Price Performance
Historical ComparisonAbout QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional nodes. The company operates in one operating segment only.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.